Wall Street is positive on Clarus Therapeutics Holdings Inc (CRXT). On average, analysts give Clarus Therapeutics Holdings Inc a Strong Buy rating. The average price target is $13.8, which means analysts expect the stock to rise by 206.67% over the next twelve months. That average ranking earns Clarus Therapeutics Holdings Inc an Analyst Rating of 70, which is better than 70% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating CRXT a Strong Buy today. Find out what this means to you and get the rest of the rankings on CRXT!